Current Financial Report 2014 for BioRegion Regensburg

The number of biotechnology companies (core biotech definition CapGemini Consulting) has remained the same as the previous year at 29. The number of biotech employees grew significantly from 1,024 to 1,224 (+ 14%), which reflects the good current economic climate particularly in the service companies in the region. Also the total number of life science companies remained at 48 - the same level as the previous year. The total number of employees at the cutoff date 31.12.2014 at 3,683 was again significantly greater than the previous year at 3,369 employees (+ 9.3%).

In the anniversary year of 2014 the BioPark celebrated its 15 year existence. A reason for the managing directors Dr. Thomas Diefenthal and Dieter Daminger to take stock of this. 41.1 million € alone was invested in the buildings at the University Campus of Regensburg. Of this the State of Bavaria invested 20.6 million €, the Federal Government 9 million, the City of Regensburg 5.6 million €, the BioPark GmbH itself 4.3 million € and the European Union 0.9 million €. With the commissioning of BioPark I (2001), BioPark II (2006) and lastly BioPark III (2011), today the BioPark  accommodates on 18,000 m2 37 leaseholders with a total of 601 employees. The leaseholders come form the sectors of biotech (11), diagnostics/analytics (7), medical technology (3), pharmaceuticals (1) services and service providers (9) and others (5), e.g. an in-house child care facility. The 37 leaseholders are distributed between companies (11), start-ups (5), university institutions (9), service providers (9) and others (2).

The CEO Dr. Thomas Diefenthal sees no reason to rest up with the current tenancy utilization at 93.6 %; "In fact we can always settle another company at the BioPark, as main growth is derived predominantly from our successful companies on-site", he said commenting on the numbers. Dr. Diefenthal sees the situation with start-ups to be increasingly critical. "Growth is lessening and of this start-ups are moving very sporadically into our center. "The main problem is the financing and awareness-raising of start-ups". The fields of talent and technology scouting, entrepreneurship, and other investment models are where Dr. Diefenthal sees the need for action.